Truveta

factnew Truveta raised a $320M Series C in January 2025 from 17 of its member health systems plus strategic investors Regeneron ($119.5M; its Regeneron Genetics Center will sequence the exomes of the first 10 million volunteers) and Illumina ($20M), pushing its valuation above $1B and funding the launch of the Truveta Genome Project.

factnew Both Series C strategic investors name Truveta in their SEC filings — Regeneron in its FY2024 and FY2025 10-Ks and proxy, and Illumina in its Q4-2024 earnings release — giving the privately held data company recurring visibility in public-company disclosures (EDGAR full-text search returns 17 filings mentioning Truveta in the window).

factnew Truveta launched Truveta Intelligence on April 28, 2026 — an AI/natural-language analytics interface over de-identified EHR data from 130M+ patients (up from the 120M+ figure cited in 2025) that lets users query live clinical data on patient journeys, treatments, and outcomes, compressing evidence generation 'from months to minutes' for trial design, commercialization, and population-health use cases.

factnew Truveta launched Truveta Live Link on January 13, 2026 — a prospective research solution that lets life-science organizations securely connect their own proprietary data with daily-updated real-world clinical data to generate forward-looking, regulatory-grade evidence (HIPAA- and HITRUST-certified, multimodal EHR plus linked economic outcomes); Dexcom is named as an early user.

factnew On February 12, 2025 Truveta Data expanded beyond EHR-only (120M+ patients from 900+ hospitals and 20,000 clinics) to add 200M+ patients of closed claims, with 120M+ patients linked across EHR and claims — repositioning the asset as regulatory-grade safety/effectiveness data for HEOR, pharmacovigilance, and comparative-effectiveness research; CEO Terry Myerson framed it as data that can replace traditional trials and registries.

factnew Truveta's consortium now spans ~30 health systems representing more than 18% of all daily clinical care in the US, and the company says it is trusted by 40+ healthcare and life-science customers — a compounding data network effect (more systems feed more data, which attracts more customers) that is the core moat.

factnew Truveta announced regulatory and audit capabilities in June 2024 to support customer real-world-evidence submissions to the FDA and other global regulatory authorities, explicitly positioning its 'regulatory-grade' EHR data (then 100M+ patients across 30 systems) for use in marketing submissions — the foundation under its 2026 'regulatory-grade' product messaging.

factnew 32 PubMed-indexed studies in the trailing window cite Truveta data, spanning cardiology (heart-failure GDMT trajectories, Impella vs IABP), GLP-1/semaglutide pregnancy outcomes, Alzheimer's antipsychotic comparative mortality, MMR vaccination gaps, and a Medicare carotid-stenting coverage analysis — plus a Truveta-authored record-linkage methods paper — evidencing clinical-depth RWD (labs, vitals, outcomes) used across many therapeutic areas.

factnew Truveta publishes recurring public 'monitoring reports' as medRxiv preprints — including GLP-1 RA prescribing trends and respiratory-virus hospitalizations, updated through 2025 — a research-as-marketing motion that seeds visibility and routes readers to studio.truveta.com.

factnew The CDC awarded Truveta Inc a ~$10.2M 'data gathering and reporting' contract (period of performance starting January 18, 2024), preceded by an earlier 2023 vehicle — demonstrating a federal public-health RWD channel distinct from Truveta's life-science customer base.

factnew The FDA maintains an active Real-World Evidence program that uses RWD/RWE across the medical-product lifecycle for pre- and post-market effectiveness and safety, and continues to advance it (e.g., a December 2025 FDA Grand Rounds on advancing RWE in regulatory decision-making) — a structural, demand-side tailwind that rewards 'regulatory-grade' RWD positioning of the kind Truveta is building toward.

factnew Truveta launched a real-time clinical trials solution on January 27, 2026 (distinct from Live Link, launched Jan 13) — letting sponsors build regulatory-grade external control arms and single-arm real-world studies, prioritize trial-ready sites/investigators, and identify eligible patients in real time (including for rare-disease and late-stage studies); the announcement cites advancing Baylor Scott & White as a net-new trial site and building an external control arm characterizing anemia progression and transfusion dependence.

factnew Truveta appointed John D. Seeger, PharmD, DrPH, FISPE — a 30-year pharmacoepidemiologist (formerly Optum, RTI Health Solutions, and Harvard) — as Senior Vice President of Truveta Evidence Services on February 9, 2026, a hire aimed squarely at regulatory-grade RWE credibility for drug-safety and comparative-effectiveness studies.

factnew Robin Damschroder, FACHE (EVP, CFO and President of the Value-Based Enterprise at Henry Ford Health) was appointed Chair of Truveta's Board of Directors on March 31, 2026, succeeding Providence CEO Rod Hochman, MD — reinforcing that Truveta is governed by its member health systems; note this is a board-chair appointment, not the hire of a Truveta CFO.

factnew Truveta presented at ISPOR 2026 (a theater session, 'Minutes, Not Months: AI-Enabled Insights to Drive Evidence Strategy,' plus research posters spanning maternal, cardiovascular, oncology, and mental-health topics) and at AMCP 2026 (a real-world poster on lecanemab adherence and MRI-monitoring patterns) — independent venue validation of its RWE/HEOR positioning.

factnew The base TRUVETA wordmark is registered to Providence Health & Services-Washington (USPTO serial 88413464), not Truveta Inc, while Truveta Inc holds the product marks (TRUVETA STUDIO, reg. #7317479; plus TRUVETA PROSE and TRUVETA OPINION applications) — a concrete legal artifact of the founder/member-owned consortium structure.

factnew Truveta's data page details its clinical depth — 130M+ EHR patients, 7B+ clinical notes, 100M+ imaging studies, 45M+ devices, and 200M+ closed-claims patients across 100+ commercial payers plus Medicare and Medicaid (claims back to 2016), daily refreshed and US-only; notably it does NOT publish how many patients are matched across BOTH EHR and claims, so the earlier '120M+ linked' figure is best read as capability framing rather than a verified matched cohort.

factnew The CDC awarded Truveta Inc a ~$10.2M 'data gathering and reporting' contract (period of performance starting January 18, 2024), preceded by an earlier 2023 vehicle — demonstrating a federal public-health RWD channel distinct from Truveta's life-science customer base.

factnew The FDA maintains an active Real-World Evidence program that uses RWD/RWE across the medical-product lifecycle for pre- and post-market effectiveness and safety, and continues to advance it (e.g., a December 2025 FDA Grand Rounds on advancing RWE in regulatory decision-making) — a structural, demand-side tailwind that rewards 'regulatory-grade' RWD positioning of the kind Truveta is building toward.